Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood marker may reveal hidden heart risk in new hypertension patients

NCT ID NCT07480265

Knowledge-focused Sponsor: Necmettin Erbakan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is checking whether people newly diagnosed with high blood pressure who also have high homocysteine levels are more likely to have early signs of heart stiffness. Researchers will measure homocysteine in blood and use ultrasound to look at heart function in 500 adults. The goal is to see if this blood test can help spot heart risk earlier.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors identify hypertensive patients at higher risk for heart problems earlier, leading to better monitoring or treatment.
What could go wrong
This is an observational study, not a treatment trial. It only looks for a link, so it won't prove cause and effect or offer a new therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults with newly diagnosed essential hypertension evaluated at a single tertiary care center, who undergo clinical assessment, laboratory testing, ambulatory blood pressure monitoring, electrocardiography, and echocardiographic evaluation including diastolic function and strain analysis.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older * Newly diagnosed essential hypertension within the previous 6 months * Ability and willingness to provide informed consent * Availability for clinical evaluation, laboratory testing, ambulatory blood pressure monitoring, electrocardiography, and transthoracic echocardiography Exclusion Criteria: * Resistant hypertension * Secondary hypertension * Acute coronary syndrome within the previous 6 months * Major surgery within the previous 6 months * Known heart failure * Pulmonary hypertension * Congenital heart disease * Atrial fibrillation or atrial flutter * Moderate or severe valvular heart disease * Chronic kidney disease * Anemia * Current folate, vitamin B12, or vitamin B6 supplementation or treatment * Inadequate echocardiographic image quality for strain analysis * Known systemic conditions that may significantly affect plasma homocysteine levels

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diastolic dysfunction are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential hypertension hyperhomocysteinemia hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diastolic dysfunction Hyperhomocysteinemia Hypertension (HTN)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Necmettin Erbakan University Meram Faculty of Medicine

    RECRUITING

    Konya, Meram, 42080, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.